非小细胞肺癌脑转移且预后不良特征患者的管理:多国放射治疗推荐存在异质性
该多国专家共识项目向7名放射肿瘤学家分发17例非小细胞肺癌脑转移病例(颅内外病变范围、组织学、年龄及预后因素各异),收集治疗推荐。结果显示全脑放疗推荐比例最高仅为3/7,多数专家推荐立体定向放射外科或分次立体定向放疗(包括5-7个病灶者),支持治疗推荐较少(0-2人),各病例推荐差异大,常出现3或4种不同推荐。
要点
- 全脑放疗推荐比例低,任一患者最高仅3/7名专家推荐。
- 多数专家对所有17例患者均推荐某种局部治疗,SRS/SFRT常被推荐,包括5-7个病灶者。
- 仅0-2名专家推荐支持治疗,各病例推荐差异大,常出现3或4种不同推荐。
核心结论
- 全脑放疗不常被推荐;即使患者预后不良特征使专家意识到临终前无效治疗风险增加,SRS/SFRT仍比支持治疗更常被推荐,除非患者决定放弃积极治疗。
研究设计与样本
- 建立多国专家放射肿瘤学家联盟,向7名放射肿瘤学家分发17例非小细胞肺癌脑转移病例,允许其同事参与提供治疗推荐;病例在颅内外病变范围、组织学、年龄及其他预后因素上不同,推荐以表格形式汇总以提供指导。
主要发现
- 关于是否愿意将17例患者纳入QUARTZ试验,纳入率低(范围0/7至3/7)。
- 不推荐试验纳入的专家提供了治疗推荐,大多数患者建议差异广泛,常见3或4种不同推荐。
- 总体而言,推荐支持治疗的专家少(0-2名)。
- 多数专家对所有17例患者建议某种局部治疗,SRS或SFRT常被许多专家推荐,包括5-7个病灶者。
- 任一患者中推荐全脑放疗的最高比例为3/7;对于大小不一的多发转移,专家常建议切除、术后SRS/SFRT及对未处理病灶行SRS/SFRT的组合。
关键数值与推荐
- 全脑放疗推荐最高比例:3/7。
- 支持治疗推荐专家数:0-2名。
- QUARTZ试验纳入意愿率范围:0/7至3/7。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Different management options exist for patients with brain metastases from non-small cell lung cancer (NSCLC), patients whose treatment with whole brain radiotherapy (WBRT) has become more controversial over the last decade. It is not trivial to find the optimal balance of over- versus undertreatment in these patients. Several recent trials, including the randomized QUARTZ trial now influence the decision to recommend or withhold WBRT for patients with unfavorable prognosis, and similarly, for favorable prognosis patients, the balance between radiosurgery alone or WBRT has become a nuanced decision. Additionally, the availability of intracranially active targeted agent for some subsets of these patients has added another layer of complexity to the decision-making. METHODS: A multinational consortium of expert radiation oncologists was established with the aim of compiling treatment recommendations for challenging scenarios, in this case the choice between optimal supportive care (SC), WBRT and other types of radiation therapy (RT). We distributed 17 cases to 7 radiation oncologists who were allowed to involve coworkers to provide their treatment recommendations. The cases differed in extra- and intracranial disease extent, histology, age and other prognostic factors. Expert recommendations were tabulated with the aim of providing guidance. RESULTS: Regarding willingness to include the 17 patients in the QUARTZ trial, the rates of trial inclusion were low (range 0/7 to 3/7). Experts not recommending trial inclusion provided their treatment recommendations. These suggestions differed widely for most of the patients. It was not uncommon to see 3 or 4 different recommendations. In general, few (0-2) recommended SC. Some kind of local treatment was suggested by the majority of experts for all 17 patients. Commonly, stereotactic single-fraction radiosurgery (SRS) or stereotactic fractionated radiotherapy (SFRT) were recommended by many experts, also for patients with 5-7 lesions. The highest proportion of recommendations towards WBRT in any patient was 3/7. It was also quite common for patients with multiple metastases of varying size that experts suggested combinations of resection, post-operative SRS/SFRT and SRS/SFRT to intact lesions. Despite recommending active treatment, experts were often willing to include the patients in a hypothetical protocol investigating radiotherapy utilization in the last 30 days of life (assessment of factors predicting early death). CONCLUSIONS: WBRT was infrequently recommended. Even in patients with adverse prognostic features that raised the experts' awareness of an increased risk for futile treatment near the end of life, SRS/SFRT were more often recommended than optimal supportive care, unless a patient decided to forego active treatment.
引用
- Nieder C, Guckenberger M, Gaspar LE, et al. Management of patients with brain metastases from non-small cell lung cancer and adverse prognostic features: multi-national radiation treatment recommendations are heterogeneous. Radiat Oncol. 2019. PMID: 30770745. doi:10.1186/s13014-019-1237-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。